Advertisement

Besondere Fälle der Epiphyseolysis capitis femoris

Endokrinopathien, Hormontherapie und andere seltene Ursachen
  • T. WirthEmail author
  • O. Eberhardt
  • D. Cerkez
  • F. Fernandez
Leitthema

Zusammenfassung

Die Epiphyseolysis capitis femoris kann in etwa 5 % der Fälle durch atypische Ursachen ausgelöst werden. Die betroffenen Patienten weisen oft ein vom typischen Erkrankungszeitraum zwischen dem 10. und 16. Lebensjahr abweichendes Alter auf. Die Ursachen einer atypischen ECF sind vielfältig und reichen von verschiedenen endokrinen Ursachen über renale Ursachen bis zu Folgen einer Chemotherapie oder Bestrahlung. Die diagnostischen und therapeutischen Maßnahmen müssen um die Abklärung und Behandlung der endokrinologischen Ursachen erweitert werden. Die rein orthopädische Therapie orientiert sich strikt an den Grundsätzen der Behandlung der idiopathischen Fälle, trägt aber dem oft geringeren Lebensalter des Patienten und der veränderten Knochenqualität Rechnung.

Schlüsselwörter

Adoleszente Coxa vara Endokrine Erkrankungen Wachstumshormonmangel Hypothyreose Renale Osteodystrophie 

Abkürzungen

ECF

Epiphyseolysis capitis femoris

IGF-1

„Insulin-like growth factor-1“

Specific cases of slipped capital femoral epiphysis

Endocrinopathies, hormone therapy and other rare causes

Abstract

In slipped capital femoral epiphysis (SCFE) atypical causes can be found in about 5% of cases. The patients’ age differs from the typical age of SCFE patients of between age 10 and 16. There are numerous causes of atypical SCFE: different endocrine disorders, sequelae of chronic renal failure and effects of radiation and chemotherapy on the proximal femoral physis. The diagnostic and therapeutic procedures must be expanded to the search for and treatment of endocrinological disorders. Orthopaedic treatment follows the principles applied to patients with idiopathic SCFE. However, the specific treatment modalities which arise from different patient ages and bone qualities are taken into account.

Keywords

Adolescent coxa vara Endocrine diseases Growth hormone deficiency Hypothyroidism Renal osteodystrophy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

T. Wirth, O. Eberhardt, D. Cerkez und F. Fernandez geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Azzopardi T, Sharma S, Bennet GC (2010) Slipped capital femoral epiphysis in children aged less than 10 years. J Pediatr Orthop B 19:13–18CrossRefGoogle Scholar
  2. 2.
    Chung CH, Ko KR, Kim JH, Shim JS (2019) Clinical and radiographic characteristics of atypical slipped capital femoral epiphysis. J Pediatr Orthop.  https://doi.org/10.1097/BPO.0000000000001339 Google Scholar
  3. 3.
    Docquier PL, Mousny M, Jouret M, Bastin C, Rombouts JJ (2004) Orthopaedic concerns in children with growth hormone therapy. Acta Orthop Belg 70:299–305Google Scholar
  4. 4.
    El Scheich T, Marquard J, Westhoff B, Krauspe R, Schneider A, Cupisti K, Oh J, Meissner T, Mayatepek E, Klee D (2012) Approach to the management of slipped capital femoral epiphysis and primary hyperparathyroidism. J Pediatr Endocrinol Metab 25:407–412CrossRefGoogle Scholar
  5. 5.
    Haidar RK, Nasrallah MP, Der-Boghossian AH, Ghanem IB (2011) Orthopedic complications related to growth hormone therapy in a pediatric population. J Pediatr Orthop B 20:57–61CrossRefGoogle Scholar
  6. 6.
    Ippolito E, Mickelson MR, Ponseti IV (1981) A histochemical study of slipped capital femoral epiphysis. J Bone Joint Surg Am 63A:1109–1113CrossRefGoogle Scholar
  7. 7.
    Liu SC, Tsai CC, Huang CH (2004) Atypical slipped capital femoral epiphysis after radiotherapy and chemotherapy. Clin Orthop Relat Res 426:212–218CrossRefGoogle Scholar
  8. 8.
    Loder RT, Wittenberg B, DeSilva G (1995) Slipped capital femoral epiphysis associated with endocrine disorders. J Pediatr Orthop 15:349–356CrossRefGoogle Scholar
  9. 9.
    Loder RT, Hensinger RN (1997) Slipped capital femoral epiphysis associated with renal failure osteodystrophy. J Pediatr Orthop 17:205–211CrossRefGoogle Scholar
  10. 10.
    Loder RT, Hensinger RN, Alburger PD, Aronsson DD, Beaty JH, Roy DR, Stanton RP, Turkr R (1998) Slipped capital femoral epiphysis associated with radiation therapy. J Pediatr Orthop 18:630–636CrossRefGoogle Scholar
  11. 11.
    Loder RT, Greenfield MLVH (2001) Clinical characteristics of children with atypical and idiopathic slipped capital femoral epiphysis: description of the age–weight test and implications for further diagnostic investigation. J Pediatr Orthop 21:481–487Google Scholar
  12. 12.
    Loder RT, O’Donnell PW, Didelot WP, Kayes KJ (2006) Valgus slipped capital femoral epiphysis. J Pediatr Orthop 26:594–600CrossRefGoogle Scholar
  13. 13.
    Loder RT, Starnes T, Dikos G (2006) Atypical and typical (idiopathic) slipped capital femoral epiphysis. Reconfirmation of the age-weight test and description of the height and height-age test. J Bone Joint Surg Am 88-A:1574–1581CrossRefGoogle Scholar
  14. 14.
    Mostoufi-Moab S, Isaacoff EJ, Spiegel D, Gruccio D, Ginsberg JP, Hobbie W, Shults J, Leonard MB (2013) Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. Pediatr Blood Cancer 60:1766–1771CrossRefGoogle Scholar
  15. 15.
    Müller W (1926) Die Entstehung von coxa valga durch Epiphysenverschiebung. Beitr Klin Chir 137:148–164Google Scholar
  16. 16.
    Oppenheim WL, Bowen RE, McDonough PW, Funahashi TT, Salusky IB (2003) Outcome of slipped capital femoral epiphysis in renal osteodystrophy. J Pediatr Orthop 23:169–174Google Scholar
  17. 17.
    Pass C, Macrae VE, Ahmed SF, Farquharson C (2009) Inflammatory cytokines and the GH/IGF-I axis: novel actions on bone growth. Cell Biochem Funct 27:119–127CrossRefGoogle Scholar
  18. 18.
    Perry DC, Metcalfe D, Costa ML, van Staa T (2017) A nationwide cohort study of slipped capital femoral epiphysis. Arch Dis Child 102:1132–1136CrossRefGoogle Scholar
  19. 19.
    Shank CF, Thiel EJ, Klingele KE (2010) Valgus slipped capital femoral epiphysis: prevalence, presentation, and treatment options. J Pediatr Orthop 30:140–146CrossRefGoogle Scholar
  20. 20.
    Siebler T, Robson H, Shalet SM, Williams GR (2001) Glucocorticoids, thyroid hormone and growth hormone interactions: implications for the growth plate. Horm Res 56(Suppl 1):7–12Google Scholar
  21. 21.
    Sikora P, Zajaczkowska M, Raganowicz T, Borzecka H, Gregosiewicz A, Konrad M (2013) Bilateral slipped capital femoral epiphysis in a male adolescent with familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), chronic renal failure, and severe hyperparathyroidism. Eur J Pediatr 172:1551–1555CrossRefGoogle Scholar
  22. 22.
    van der Eerden BCJ, Karperien M, Wit JM (2003) Systemic and local regulation of the growth plate. Endocr Rev 24:782–801CrossRefGoogle Scholar
  23. 23.
    Weiner D (1996) Pathogenesis of slipped capital femoral epiphysis: current concepts. J Pediatr Orthop B 5:67–73CrossRefGoogle Scholar
  24. 24.
    Wirth T (2011) Epiphyseolysis capitis femoris. Z Orthop Unfall 149:21–41CrossRefGoogle Scholar
  25. 25.
    Witbreuk M, van Kemenade FJ, van der Sluijs JA, Jansma EP, Rotteveel J, van Royen BJ (2013) Slipped capital femoral epiphysis and its association with endocrine, metabolic and chronic diseases: a systematic review of the literature. J Child Orthop 7:213–223CrossRefGoogle Scholar
  26. 26.
    Yngve DA, Moulton DL, Evans EB (2005) Valgus slipped capital femoral epiphysis. J Pediatr Orthop B 14:172–176CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • T. Wirth
    • 1
    Email author
  • O. Eberhardt
    • 1
  • D. Cerkez
    • 1
  • F. Fernandez
    • 1
  1. 1.Orthopädische Klinik, OlgahospitalKlinikum StuttgartStuttgartDeutschland

Personalised recommendations